Comparison of Transcatheter Aortic Valve Replacement With Surgical Aortic Valve Replacecment: A Prospective, Multicenter, International, Randomized Controlled, Non-inferiority Study for Bicuspid Aortic Valve Stenosis (PROMIS-BAV)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Aortic Stenosis
- Sponsor
- Shanghai MicroPort CardioFlow Medtech Co., Ltd.
- Enrollment
- 452
- Locations
- 1
- Primary Endpoint
- Incidence of composite endpoint events (all-cause mortality, all strokes, and re-hospitalizations [surgery, valve or heart failure related re-hospitalizations])
- Status
- Enrolling by Invitation
- Last Updated
- 7 months ago
Overview
Brief Summary
To evaluate the safety and effectiveness of the Transcatheter aortic valve and retrievable delivery system (VitaFlow Liberty®) for the treatment of severe bicuspid aortic valve (BAV) stenosis.
Detailed Description
Transcatheter aortic valve replacement (TAVR) has emerged as the first-line treatment for symptomatic severe AS currently, while TAVR for bicuspid aortic valve (BAV) stenosis has not been well demonstrated in randomized controlled trials, thus more randomized controlled studies of TAVR vs. SAVR are still needed to provide strong evidence that TAVR treatment for patients with BAV stenosis has good safety and effectiveness. This study is a prospective, international multicenter, randomized controlled, non-inferiority clinical study, in which the study device (VitaFlow Liberty®) for TAVR is to be demonstrated as non-inferior to the control device (a commercially available surgical bioprosthetic valve) for SAVR in terms of the incidence of composite endpoint events (all-cause mortality, all strokes and re-hospitalizations) at 12 months postoperatively. In this study, 452 eligible subjects will be randomly assigned to the study group (n=226) or the control group (n=226) in a 1:1 ratio. The subjects in study group will be treated with the TAVR surgery using the study device (VitaFlow Liberty®) , while the subjects in control group will be treated with the SAVR surgery using the control device (a commercially available surgical bioprosthetic valve), and clinical follow-ups will be performed at discharge (or 7 days after surgery), 30 days, 6 months, 12 months, and 2, 3, 4, 5 years after surgery, respectively.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject aged ≤ 75 years;
- •With symptomatic severe bicuspid aortic stenosis, defined as: peak flow velocity ≥ 4.0m/s, or mean trans-aortic pressure gradient ≥ 40mmHg, or aortic orifice area (AVA) ≤ 1.0cm2 (or AVA index ≤ 0.6cm2/m2) confirmed by echocardiography；
- •New York Heart Association (NYHA) cardiac function classification ≥ Class II;
- •With an intermediate or low risk of surgical procedures (STS score ≤8%) assessed by the local heart team;
- •Voluntarily participate in this study and sign the informed consent form.
Exclusion Criteria
- •Known allergy or resistance to study device and control device components such as nitinol or contrast media;
- •Known contraindication or allergy to anticoagulant or antiplatelet medications and inability to tolerate the anticoagulant or antiplatelet therapy;
- •Known presence of active infective endocarditis or other active infection;
- •Known presence of severe vascular disease that precludes safe implantation of the prosthetic valve;
- •Ascending aorta width ≥50mm;
- •Previous prosthetic valve implantation (mechanical or bioprosthetic) in any heart place;
- •The aortic root anatomy not suitable for transcatheter aortic valve implantation confirmed by preoperative imaging (including aortic root calcification that influence the sufficient dilatation of the rposthetic valve);
- •Intracardiac mass, left ventricular or left atrial thrombus, vegetations confirmed by preoperative echocardiography;
- •Acute myocardial infarction (defined as Q-wave MI or non-Q-wave MI) within 30 days prior to surgery;
- •Invasive therapeutic cardiac surgery within 30 days prior to surgery (except for temporary pacemaker or implantable cardioverter-defibrillator implantation);
Outcomes
Primary Outcomes
Incidence of composite endpoint events (all-cause mortality, all strokes, and re-hospitalizations [surgery, valve or heart failure related re-hospitalizations])
Time Frame: 12 months postoperatively
The composite endpoint event at 12 months postoperatively refers to all-cause mortality, all strokes, and re-hospitalizations related to procedure, valve or heart failure that occur within 12 months postoperatively.
Secondary Outcomes
- New York Heart Association grading assessment of cardiac function(Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively)
- Quality of life assessment (Kansas City Cardiomyopathy Questionnaire score)(30 days, 6 months, 12 months postoperatively)
- Incidence of all strokes(30 days, 6 months, 12 months, 2 to 5 years postoperatively)
- Incidence of myocardial infarction(Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of life-threatening or disabling major bleeding(30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of acute kidney injury (AKI)(Discharge, 30 days postoperatively)
- Incidence of conduction disturbance and arrhythmias(30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of permanent pacemaker implantation(30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of serious vascular complications(30 days, 6 months, 12 months postoperatively)
- Incidence of Bioprosthetic valve dysfunction (BVD)(12 months, 2-5 years postoperatively)
- Bioprosthetic valve dysfunction (BVF)(12 months, 2-5 years postoperatively)
- Re-hospitalization related to procedure, valve or heart failure(30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of adverse events (AEs)(throughout the clinical study period)
- Device success rate(30 days postoperatively)
- Prosthetic valve performance evaluation(30 days, 6 months, 12 months, 2-5 years postoperatively)
- All-cause mortality(30 days, 6 months, 12 months, 2-5 years postoperatively)
- Incidence of major adverse cardiovascular and cerebrovascular events (MACCE)(30 days, 6 months, 12 months postoperatively)
- Incidence of other TAVR-related complications(Immediately, 30 days, 6 months, 12 months, 2-5 years postoperatively)
- Moderate to severe structural valvular deterioration (HVD)(12 months, 2-5 years postoperatively)
- Incidence of serious adverse events (SAEs)(throughout the clinical study period)